Rabies Vaccine for Lactation

AIM's conventional and serum-free Rabies Vaccine for Lactation, through strict control of impurity residues and elimination of bovine-derived allergen risks, have been clinically proven to be safe for lactating women. They not only quickly build an immune barrier in the mother but also provide passive immunity to the infant through breast milk, achieving dual protection for both mother and child.

Pain Points in Prevention and Control of Rabies Exposure during Lactation

Lactating women belong to a special immunization population, who need to not only protect themselves from the threat of the rabies virus, but also worry about the impact of vaccine components on breastfed infants.

Clinical data shows that if lactating women experience Category III rabies exposure, the fatal risk without timely prevention is the same as that of the general population, while blindly refusing vaccination will miss the best protection opportunity.

Core Principles of Immunization during Lactation

1. No Vaccination Contraindications: Rabies is a fatal disease, and lactation is not a contraindication for vaccination. The prevention procedure should be initiated immediately after exposure.

2. Balance the Safety of Mother and Infant: Prioritize vaccines with low impurities and no preservatives. Breastfeeding can be carried out normally after vaccination, and there is no need to suspend breastfeeding.

3. Standardized Immunization Schedule: The full course of vaccination must be completed to ensure that the antibody level meets the standard, so as to build dual protection for the mother and the infant.

AIM Honor Vaccine: Exclusive Protection Solution for Lactation Period

The Conventional Vero Cell Rabies Vaccine and Serum-free Vero Cell Rabies Vaccine launched by AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. are the optimal choices for lactating people:

1. Safety Adapted to the Lactation Stage

The conventional vaccine strictly controls impurity residues, with residual bovine serum albumin ≤10ng per dose and residual Vero cell protein ≤4μg per dose, which is much lower than the industry standard. Clinical verification shows that vaccine components will not cause adverse effects on infants through breast milk.

The serum-free vaccine is cultured without bovine serum throughout the entire process, completely eliminating the allergy risks of bovine-derived components. The only adverse reaction is mild local pain, with no serious systemic reactions, so lactating women can be vaccinated with peace of mind.

2. Guarantee of Highly Effective Immunity

Both vaccines achieve a 100% antibody seroconversion rate 14 days after vaccination, and the neutralizing antibody level far exceeds the WHO 0.5IU/ml protection threshold.

In addition, the antibodies can provide passive immunity to infants through breast milk, achieving dual protection for the mother and the infant. The immunization schedule is 5-dose intramuscular injection on days 0, 3, 7, 14, and 28, with the deltoid muscle of the upper arm as the preferred vaccination site.